LLY vs TKNO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
TKNO exhibits severe financial weakness with a Piotroski F-Score of 1/9, indicating critical operational deterioration. While the company maintains a strong liquidity buffer with a current ratio of 4.58 and low debt-to-equity (0.41), it is plagued by deep negative profit margins (-42.59%) and a completely bearish technical trend (0/100). There is a significant disconnect between the optimistic analyst target of $9.00 and the market's reality, evidenced by a 49.6% price decline over the last year. The lack of profitability and poor deterministic health scores make this a high-risk speculative play.
Compare Another Pair
Related Comparisons
LLY vs TKNO: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Alpha Teknova, Inc. (TKNO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.